Background Poly-(ADP-Ribose)-Polymerase (PARP) inhibitors are becoming important
actors of anti-neoplasic agents landscape, with recent but narrow FDA's approvals for …

Poly (ADP-ribose) polymerase-1 (PARP1) is a DNA repair enzyme highly expressed in the
nuclei of mammalian cells, with a structure and function that have attracted interest since its …

Approximately two million fractions of radiotherapy are administered in the UK every year, as
part of adjuvant, radical or palliative cancer treatment. For many tumour types, radiotherapy …

Poly-(ADP-ribose) polymerase (PARP) inhibitors act through synthetic lethality in cells with
defects in homologous recombination (HR) DNA repair caused by molecular aberrations …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors represent one of the successful
novel approaches to targeted cancer treatment. Indeed, the US Food and Drug …

Ovarian cancer is the most lethal gynecologic malignancy and the fifth most lethal cancer
type overall in women. Ovarian cancer often presents genome instability, with almost half of …

Inhibitors of poly (ADP-ribose) polymerases (PARPs), which play a key role in DNA
damage/repair pathways, have been developed as antitumor agents based on the concept …

Poly-ADP-ribose polymerase (PARP) plays an important role in DNA damage detection and
repair. PARP inhibitors (PARPi) are a novel class of targeted agents used widely in the …

Simple Summary Targeted therapy has revolutionised oncological treatments in cancer with
great efficacy and a more tolerable side effect profile as compared to standard …

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze the addition
of poly (ADP-ribose)(PAR) subunits onto themselves and other acceptor proteins. PARPs …